Oramed Pharmaceuticals
ORMP
7 hedge funds and large institutions have $216K invested in Oramed Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
15% more capital invested
Capital invested by funds: $188K → $216K (+$28K)
13% less funds holding
Funds holding: 8 → 7 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Platinum Management
New York
|
+$189K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.77K |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$125K |
| 2 |
MA
MUFG Americas
New York
|
-$7K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$171 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PM
1
Platinum Management
New York
| $165K | +$189K | +26,573 | New |
|
|
FNBT
2
FineMark National Bank & Trust
Fort Myers,
Florida
| $22K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $14K | +$8.77K | +1,233 | +112% |
|
|
4
Wells Fargo
San Francisco,
California
| $8K | -$171 | -24 | -2% |
|
|
U
5
UBS
Zurich,
Switzerland
| $4K | +$1.09K | +153 | +37% |
|
|
HRIA
6
Haberer Registered Investment Advisor
Cincinnati,
Ohio
| $2K | – | – | – |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
CS
8
Credit Suisse
Zurich,
Switzerland
| – | -$125K | -15,272 | Closed |
|
|
MA
9
MUFG Americas
New York
| – | -$7K | -834 | Closed |
|
ORMP Hedge Fund Activity: Q3 2013 in Review
7 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2013, worth a combined $216K — up 15% from $188K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ORMP and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Platinum Management, opening a new position worth an estimated $189K. The largest seller was Credit Suisse, exiting entirely with an estimated $125K sold.
- 7 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2013, down from 8 in Q2 2013.
- Funds reported $216K of Oramed Pharmaceuticals stock for Q3 2013, up 15% quarter-over-quarter.
- 1 fund opened new Oramed Pharmaceuticals positions in Q3 2013 and 2 closed out, a net change of -1 holder.
- The largest Oramed Pharmaceuticals buyer in Q3 2013 was Platinum Management, an estimated $189K added.
- The largest Oramed Pharmaceuticals seller in Q3 2013 was Credit Suisse, an estimated $125K sold.
Based on aggregated 13F filings for Q3 2013.